Stonegate Capital Partners has updated its coverage on OS Therapies Inc. (NYSE: OSTX), highlighting significant regulatory progress for the company's lead candidate, OST-HER2, in recurrent, fully resected, pulmonary metastatic osteosarcoma. The key development is greater regulatory clarity: the European Medicines Agency (EMA) has initiated a rolling review of the OST-HER2 Conditional Marketing Authorization dossier, while the EMA and Australia's Therapeutic Goods Administration (TGA) have aligned on 3-year overall survival (OS) as the approvable efficacy endpoint. This alignment shifts OST-HER2 from Phase 2b validation toward a defined global approval pathway.
Management has also positioned seroconversion biomarker data as supportive surrogate efficacy evidence, moving the investment debate from early proof-of-concept toward execution across a dense 2026 catalyst calendar. Key milestones include 2.5-year OS data in mid-2Q26, FDA and MHRA meetings in 2Q26, Phase 3 initiation in Australia in 3Q26, 3-year OS data in early 4Q26, and a potential EMA CMA decision in 4Q26. For more details, see the full announcement here.
Stonegate highlights that regulatory clarity is the core value inflection. The EMA rolling review, TGA endpoint alignment, MHRA ATMP designation, and 2026 FDA/MHRA meetings shift OST-HER2 from Phase 2b validation toward an executable global approval pathway. Survival data remain the key catalyst stack. Mid-2Q26 2.5-year OS data and early-4Q26 3-year OS data should determine whether OSTX can complete the EMA CMA submission and sustain accelerated-access momentum. Financing and PRV optionality bridges the regulatory window. The $5.25 million raise plus expected $4.0 million non-dilutive funding supports 2026 catalysts, while a potential PRV remains a meaningful approval-contingent valuation lever, with the latest public transaction at $205 million.
OS Therapies is advancing materially through late-stage regulatory and commercialization preparation. The company's progress underscores the importance of OST-HER2 as a potential treatment for osteosarcoma patients with limited options. Stonegate Capital Partners, a leading capital markets advisory firm, provides investor relations, equity research, and institutional investor outreach services for public companies. Its affiliate, Stonegate Capital Markets, offers investment banking services. For more information, contact Stonegate Capital Partners at (214) 987-4121 or visit their website.
